The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Radiotheranostics Market Expected To Scale Between 2026 And 2030?
The radiotheranostics market size has experienced rapid growth in recent years. It is anticipated to increase from $10.05 billion in 2025 to $11.43 billion in 2026, at a compound annual growth rate (CAGR) of 13.7%. This historic period’s growth can be linked to factors including the increasing use of nuclear medicine diagnostics, the expansion of oncology-focused clinical research, the availability of therapeutic radioisotopes, the rising adoption of PET and SPECT imaging, and growing collaboration between pharma and imaging providers.
The radiotheranostics market is projected to experience substantial expansion in the coming years, reaching $19.24 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.9%. This anticipated growth is primarily driven by factors such as the increasing number of approvals for radiotheranostic pharmaceuticals, heightened investments in precision oncology, the expansion of infrastructure for isotope production, a rising need for individualized cancer care, and the growing incorporation of AI in selecting treatments. Key trends expected during this period involve the wider acceptance of targeted radioligand therapies, a surge in the utilization of combined diagnostic and therapeutic isotopes, the increasing fusion of precision imaging with therapeutic approaches, the broadening of personalized oncology applications, and a stronger emphasis on targeting cancer at the molecular level.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12270&type=smp
What Major Factors Are Driving The Radiotheranostics Market Forward?
The growing incidence of cancer is anticipated to drive the expansion of the radiotheranostics market in the future. Cancer refers to a medical condition characterized by the uncontrolled proliferation and dissemination of certain body cells to other areas. In cancer treatment, radiotheranostics medicines are frequently utilized to realize personalized medicine, involving the employment of linked diagnostic and therapeutic radionuclide probes for the precise and targeted identification and therapy of particular cells, typically cancer cells, with each probe tailored to the patient’s specific health status to improve treatment effectiveness and clinical outcomes. As an illustration, the American Cancer Society, a US-based nonprofit cancer advocacy organization, reported in January 2024 that cancer cases rose to 2,001,140, an increase from 1,958,310 in 2023, representing a 2.19% growth. Consequently, the rising occurrence of cancer is a key driver for the radiotheranostics market.
How Are Segments Identified Within The Radiotheranostics Market Segment Framework?
The radiotheranostics market covered in this report is segmented –
1) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fludeoxyglucose-18F, Yttrium-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioisotopes
2) By Approach: Targeted Therapeutic, Targeted Diagnostic
3) By Application: Oncology, Non-Oncology
4) By End-Users: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By Technetium-99: Technetium-99m, Technetium-99 Pertechnetate
2) By Gallium-68: Gallium-68 DOTATATE, Gallium-68 PSMA
3) By Iodine-131: Iodine-131 For Thyroid Cancer Treatment, Iodine-131 For Hyperthyroidism Treatment
4) By Iodine-123: Iodine-123 For Thyroid Scans, Iodine-123 For Cardiac Imaging
5) By Fludeoxyglucose-18F (FDG): FDG For Oncology Imaging, FDG For Brain Imaging
6) By Yttrium-90: Yttrium-90 Microspheres For Liver Cancer, Yttrium-90 For Radioimmunotherapy
7) By Lutetium (Lu) 177: Lutetium-177 PSMA For Prostate Cancer, Lutetium-177 DOTATATE For Neuroendocrine Tumors
8) By Copper (Cu) 67: Copper-67 For Targeted Radiotherapy, Copper-67 In Clinical Trials
9) By Copper (Cu) 64: Copper-64 For PET Imaging, Copper-64 For Radiotherapy
10) By Other Radioisotopes: Radium-223, Samarium-153, Other Emerging Radioisotopes In Theranostics
Which Trends Are Impacting The Progress Of The Radiotheranostics Market?
Leading companies in the radiotheranostics market are focusing on developing innovative products to enhance the manufacturing and availability of therapeutic radioisotopes, improve the precision of treatments, and meet the growing demand for targeted cancer therapies. For example, in May 2023, Advanced Cyclotron Systems Inc., a Canada-based company that supplies and services cyclotrons primarily used for medical isotope production, introduced TR-ALPHA, a dedicated cyclotron for producing alpha-emitting radioisotopes to treat cancer. This TR-ALPHA system was designed to address the market’s need for an economical cyclotron capable of producing large quantities of Astatine-211, recognized as one of the most promising alpha-emitting radioisotopes. It is smaller, more affordable, and easier to operate than previous models, making it an ideal solution for hospitals, research institutions, and organizations aiming to efficiently produce therapeutic alpha-emitting radioisotopes.
Who Are The Companies Competing Within The Radiotheranostics Market?
Major companies operating in the radiotheranostics market are Lantheus Holdings Inc., Cardinal Health Inc., GE Healthcare Inc., Bayer AG, Novartis AG, Siemens Healthineers, Orano Med, Curium SAS, IBA Molecular, The Eckert & Ziegler Group, Advanced Accelerator Applications (AAA), Telix Pharmaceuticals Limited., Abdera Therapeutics, Blue Earth Diagnostics, Sirtex Medical Limited, Y-mAbs Therapeutics Inc., ITM Radiopharma, NorthStar Medical Radioisotopes LLC, Trasis S.A., Molecular Targeting Technologies Inc., RadioMedix Inc, Clarity Pharmaceuticals, Actinium Pharmaceuticals Inc., Navidea Biopharmaceuticals Inc.
Get The Full Radiotheranostics Market Report:
https://www.thebusinessresearchcompany.com/report/radiotheranostics-global-market-report
Where Is The Radiotheranostics Market Most Concentrated Geographically?
North America was the largest region in the radiotheranostics market in 2025. The regions covered in the radiotheranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Radiotheranostics Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/radiotheranostics-global-market-report
Browse Through More Reports Similar to the Global Radiotheranostics Market 2026, By The Business Research Company
Radiotherapy Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/radiotherapy-devices-global-market-report
Veterinary Stereotactic Radiosurgery System Market Report
Image Guided Radiation Therapy Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model